Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18025043 | 0.81 | TDP1 (0.38) | TDP1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL17696579 | 0.77 | ALDH1A1 (0.40) | TDP1L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL3532178 | 0.66 | EPHX2 (0.45) | TDP1L3MBTL1KMT2AALDH1A1USP2 | |
| SCHEMBL5571264 | 0.65 | KMT2A (0.52) | L3MBTL1MEN1KMT2AALDH1A1USP2 | |
| SCHEMBL3220536 | 0.65 | GAA (0.56) | L3MBTL1KMT2AALDH1A1USP2POLB | |
| SCHEMBL3207787 | 0.65 | EPHX2 (0.47) | TDP1L3MBTL1ALDH1A1POLBCNR2 | |
| SCHEMBL19188031 | 0.65 | THRB (0.44) | TDP1L3MBTL1ALDH1A1POLBCNR2 | |
| SCHEMBL25826322 | 0.65 | CYP1A2 (0.55) | L3MBTL1KMT2AALDH1A1USP2POLB | |
| SCHEMBL5411539 | 0.64 | GAA (0.48) | L3MBTL1KMT2AALDH1A1USP2POLB | |
| SCHEMBL4432951 | 0.64 | GAA (0.48) | L3MBTL1KMT2AALDH1A1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10967069-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-04-06 | — | — | US | disclosed |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10967069-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | TDP1 2839/4885L3MBTL1 2659/4885MEN1 3386/4885 |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | TDP1 2839/4885L3MBTL1 2659/4885MEN1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.